Unknown

Dataset Information

0

Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.


ABSTRACT: PURPOSE:The use of VEGFR TKIs for the adjuvant treatment of renal cell carcinoma (RCC) remains controversial. We investigated the effects of adjuvant VEGFR TKIs on circulating cytokines in the ECOG-ACRIN 2805 (ASSURE) trial. EXPERIMENTAL DESIGN:Patients with resected high-risk RCC were randomized to sunitinib, sorafenib, or placebo. Plasma from 413 patients was analyzed from post-nephrectomy baseline, 4 weeks, and 6 weeks after treatment initiation. Mixed effects and Cox proportional hazards models were used to test for changes in circulating cytokines and associations between disease-free survival (DFS) and cytokine levels. RESULTS:VEGF and PlGF increased after 4 weeks on sunitinib or sorafenib (P < 0.0001 for both) and returned to baseline at 6 weeks on sunitinib (corresponding to the break in the sunitinib schedule) but not sorafenib (which was administered continuously). sFLT-1 decreased after 4 weeks on sunitinib and 6 weeks on sorafenib (P < 0.0001). sVEGFR-2 decreased after both 4 and 6 weeks of treatment on sunitinib or sorafenib (P < 0.0001). Patients receiving placebo had no significant changes in cytokine levels. CXCL10 was elevated at 4 and 6 weeks on sunitinib and sorafenib but not on placebo. Higher baseline CXCL10 was associated with worse DFS (HR 1.41 per log increase in CXCL10, Bonferroni-adjusted P = 0.003). This remained significant after adjustment for T-stage, Fuhrman grade, and ECOG performance status. CONCLUSIONS:Among patients treated with adjuvant VEGFR TKIs for RCC, drug-host interactions mediate changes in circulating cytokines. Elevated baseline CXCL10 was associated with worse DFS. Studies to understand functional consequences of these changes are under way.

SUBMITTER: Xu W 

PROVIDER: S-EPMC7057142 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.

Xu Wenxin W   Puligandla Maneka M   Manola Judith J   Bullock Andrea J AJ   Tamasauskas Daniel D   McDermott David F DF   Atkins Michael B MB   Haas Naomi B NB   Flaherty Keith K   Uzzo Robert G RG   Dutcher Janice P JP   DiPaola Robert S RS   Bhatt Rupal S RS  

Clinical cancer research : an official journal of the American Association for Cancer Research 20190830 20


<h4>Purpose</h4>The use of VEGFR TKIs for the adjuvant treatment of renal cell carcinoma (RCC) remains controversial. We investigated the effects of adjuvant VEGFR TKIs on circulating cytokines in the ECOG-ACRIN 2805 (ASSURE) trial.<h4>Experimental design</h4>Patients with resected high-risk RCC were randomized to sunitinib, sorafenib, or placebo. Plasma from 413 patients was analyzed from post-nephrectomy baseline, 4 weeks, and 6 weeks after treatment initiation. Mixed effects and Cox proportio  ...[more]

Similar Datasets

2021-06-07 | E-MTAB-10586 | biostudies-arrayexpress
2021-06-07 | E-MTAB-10592 | biostudies-arrayexpress
| S-EPMC4815796 | biostudies-literature
| S-EPMC6386754 | biostudies-literature
| S-EPMC8459336 | biostudies-literature
| S-EPMC6692378 | biostudies-literature
| S-EPMC8071858 | biostudies-literature
| PRJEB45952 | ENA
| S-EPMC8548516 | biostudies-literature
| S-EPMC4767591 | biostudies-literature